Complete Monthly Cost Analysis: Wegovy vs Mounjaro UK
Understanding the Switch From Wegovy to Mounjaro: Cost Implications
When evaluating whether to switch from Wegovy to Mounjaro, monthly cost considerations play a crucial role alongside clinical factors in the UK market. Wegovy (semaglutide) operates as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) functions as a dual GIP and GLP-1 receptor agonist, representing different therapeutic approaches to weight management. The cost differential between these treatments varies significantly across the dose escalation phases, with Wegovy starting at £79.99 monthly for the 0.25mg starter dose and progressing to £209.99 for the 2.4mg maintenance dose. Understanding these cost implications helps patients make informed decisions about their long-term weight management journey.
The decision to switch from Wegovy to Mounjaro involves more than just monthly cost comparisons, as both medications require different dose escalation schedules and monitoring protocols. Mounjaro's dual mechanism may offer different clinical benefits, but this comes with its own pricing structure that patients must consider alongside their budget constraints. At EverydayMeds, our clinical team provides comprehensive guidance to help patients evaluate both the financial and therapeutic aspects of potentially switching between these prescription-only medicines.
Monthly Pricing Breakdown: Wegovy vs Mounjaro Cost Analysis
The monthly cost to switch from Wegovy to Mounjaro requires understanding both medications' complete pricing structures throughout their respective dose escalation phases. Wegovy follows a 16-week escalation protocol: 0.25mg (£79.99), 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), before reaching the 2.4mg maintenance dose (£209.99 monthly). New customers apply code FIRST40 at checkout to achieve these prices, whilst returning customers use DOSE25 for ongoing affordability. Our bundle options provide additional value, such as the Intro Duo (0.25mg & 0.5mg) at £169.99, covering the first two months of treatment.
Mounjaro's pricing structure follows its own escalation schedule, starting with lower doses and progressing to maintenance levels that may differ from Wegovy's cost profile. The annual cost implications of switching from Wegovy to Mounjaro become significant when calculating maintenance dose expenses, with Wegovy's 2.4mg maintenance costing approximately £2,520 annually at full price. However, our discount codes substantially reduce this burden, making long-term treatment more accessible for patients requiring ongoing weight management support alongside a reduced-calorie diet and increased physical activity.
Clinical Evidence Supporting the Switch From Wegovy to Mounjaro
The clinical rationale for switching from Wegovy to Mounjaro stems from their different mechanisms of action, as demonstrated in respective clinical trials. Wegovy's efficacy was established in the STEP trial programme, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside diet and exercise (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events, highlighting Wegovy's broader health benefits beyond weight management.
Mounjaro's clinical profile, established through the SURMOUNT trials, demonstrates the potential benefits of dual GIP and GLP-1 receptor activation compared to Wegovy's GLP-1-only mechanism. However, patients considering the switch from Wegovy to Mounjaro should understand that individual responses may vary, and the decision should be based on clinical assessment rather than trial comparisons alone. Both medications are prescription-only medicines requiring ongoing medical supervision and lifestyle modifications.
How Wegovy Works: GLP-1 Mechanism Before Switching
Before deciding to switch from Wegovy to Mounjaro, understanding Wegovy's mechanism helps contextualize the therapeutic differences between treatments. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which is released after meals to signal satiety. This mechanism works primarily through appetite reduction and promoting feelings of fullness after smaller meals, potentially reducing food cravings by acting on brain appetite centres. The once-weekly FlexTouch pen delivery system provides consistent medication levels throughout the week, supporting sustained appetite control. Wegovy may also slow gastric emptying, contributing to prolonged satiety and reduced caloric intake when combined with dietary modifications. This GLP-1-focused approach has been extensively studied and forms the foundation for patients' current treatment experience before considering a switch to Mounjaro's dual mechanism.
Ordering Process: Switching From Wegovy to Mounjaro
The process to switch from Wegovy to Mounjaro through EverydayMeds begins with a comprehensive 3-minute online clinical assessment evaluating your current treatment response and medical history. Our prescribers, operating under GPhC registration #9012878, review your assessment within 3 working days (or 24 hours with express service) to determine the most appropriate treatment approach. If approved for the switch, your medication is dispatched via next-day delivery using our cold-chain, temperature-controlled system to maintain medication integrity. The clinical assessment specifically addresses reasons for switching, current dose response, and any side effects experienced with your previous treatment. Our prescribers provide detailed guidance on transitioning between medications, including any necessary washout periods and new dose escalation schedules for optimal safety and efficacy.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements represent a practical advantage when evaluating the switch from Wegovy to Mounjaro, as Wegovy offers superior storage flexibility for UK patients. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This advantage proves particularly valuable for travel, work schedules, or situations where refrigeration access may be limited. Both medications require storage between 2-8°C in the refrigerator before first use, but Wegovy's extended room temperature tolerance provides greater flexibility for patients with active lifestyles. The FlexTouch pen system used for Wegovy delivery is designed for single-use weekly injections, with clear dose escalation markings to prevent dosing errors during the 16-week titration period. These practical considerations may influence your decision when weighing the switch from Wegovy to Mounjaro alongside clinical and cost factors.
Budget Planning: Long-term Costs of Switching From Wegovy to Mounjaro
Long-term budget planning for switching from Wegovy to Mounjaro requires careful consideration of maintenance dose costs and ongoing treatment duration. Wegovy's 2.4mg maintenance dose at £209.99 monthly translates to approximately £2,520 annually, though our DOSE25 discount code for returning customers significantly reduces this burden. The Ultimate Stability Trio bundle provides three months of 2.4mg maintenance supply for £649.99, offering convenience and supply security for established patients. Weight management typically requires long-term commitment, as clinical studies demonstrate that patients may regain approximately two-thirds of lost weight within one year of stopping treatment.
When planning the budget impact of switching from Wegovy to Mounjaro, patients should factor in the potential need for different monitoring requirements, dose adjustment periods, and possible differences in treatment response timelines. Our bundle pricing options, including the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99, help patients manage costs during dose escalation phases while ensuring uninterrupted treatment continuity. The financial commitment to switching treatments should be weighed against potential clinical benefits and individual treatment response patterns observed with current therapy.
Making Your Decision: Wegovy and Mounjaro Available at EverydayMeds
Both Wegovy and Mounjaro are available from EverydayMeds, and our experienced prescribers can help determine which treatment aligns with your clinical needs and budget considerations. The decision to switch from Wegovy to Mounjaro should be based on individual treatment response, tolerability, and clinical goals rather than cost alone. Our clinical team, operating under GPhC registration #9012878, provides comprehensive guidance throughout the decision-making process, ensuring that any treatment switch is clinically appropriate and safely managed. Remember that both medications are prescription-only medicines that must be used alongside a reduced-calorie diet and increased physical activity for optimal results. Your prescriber will evaluate your current treatment response, medical history, and individual circumstances to recommend the most suitable option, whether continuing with Wegovy or transitioning to Mounjaro's dual mechanism approach.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
